期刊文献+

SARS疫苗研究进展 被引量:3

Research progress on SARS vaccine
原文传递
导出
摘要 2003年世界性的流行病——严重急性呼吸综合症(SAILS)引发了各国科学家对SARS相关冠状病毒(SARS-Coy)的研究热潮。SARS-Coy是一种新的冠状病毒,其致病机制还不清楚,目前尚无有效治疗SARS的抗病毒药物,研制一种安全有效的疫苗是阻止SARS再次流行最有效的方式。目前研究较多且有发展前景的SARS疫苗有:灭活疫苗、DNA疫苗和表位疫苗等。但在SARS疫苗的研究过程中也遇到了很多问题,如没有标准的动物模型、SARS-Coy变异快等问题。所以,研发一种安全有效的SARS疫苗任重而道远。 The emergence of the severe acute respiratory syndrome (SARS) that resulted in a pandemic in 2003 spurred a flurry of interest in the SARS associated coronavirus (SARS-Cov). SARS-Cov is a new member of coronavirus, whose pathogenisis is still not clear. Now there is no effective anti-viral agent available for SARS treatment. The development of safe and effective vaccines is considered to be one of the best ways to prevent another SARS epidemic. At present, potential vaccine candidates under development include inactivated SARS vaccine, DNA vaccine, and epitope-based vaccine. However, there exist many difficulties in the development of SARS vaccines, for example, lack of an animal model that mimics human disease, frequent variation of SARS-Cov and so on. As a consequence, the development of an effective and safe SARS vaccine shoulders heavy responsibilities.
作者 曾玉红
出处 《国际免疫学杂志》 CAS 2007年第4期266-269,共4页 International Journal of Immunology
关键词 SARS 冠状病毒 SARS-Coy 疫苗 动物模型 SARS, Coronavirus, SARS-Cov, Vaccine, Animal model
  • 相关文献

参考文献20

  • 1Snijder EJ, Bredenbeek PJ, Dobbe JC, et al. Unique and conserved features of genome and proteome of SARS- coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol, 2003,331:991- 1004.
  • 2Rota PA, Oberste MS,Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science,2003,300: 1394-1399.
  • 3Li W, Moore M J, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature,2003,426 (6965) :450-454.
  • 4Wong SK, Li W, Moore MJ, et al. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem ,2004, 279(5) : 3197-3201.
  • 5Takasuka N, Fujii H, Takahashi Y, et al. Asubcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol, 2004,16(10) :1423-1430.
  • 6He Y, Zhou Y, Siddiqui P, et al. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun , 2004,325 (2) :445-452.
  • 7Qin Ee, Shi H,Tang L, et al. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine, 2006, 24(7) : 1028-1034.
  • 8Yang ZY, Kong WP, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature, 2004,428 (6982) :561-564.
  • 9Yang ZY, Werner HC, Kong WP, et al. Evasion of antibody neutralization in emerging sever acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA,2005, 102(3) :797-801.
  • 10He Y, Zhou Y, Liu S, et al. Receptor-binding domain of SARS- CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun, 2004,324(2) :773-781.

同被引文献14

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部